BioNTech SE: Pfizer and BioNTech Report New Data on Omicron

One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to

Related Keywords

Germany , United States , Canada , United Kingdom , Sylke Maas , Biontech Covid , Fosun Pharma , Linkedin , Genentech , Twitter , European Commission , Drug Administration , Exchange Commission , Pfizer , Pfizer Inc , European Union , Facebook , Roche Group , Marketing Authorization Holder , Emergency Use Authorization , Coronavirus Disease , Prescribing Information , Vaccination Providers , Caregivers Fact Sheets , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , New Technologies , Private Securities Litigation Reform Act , Quarterly Report , Biontech , Report , Data , Micron , Adapted , Bivalent , Rooster , Emonstrating , Mproved , Immune , Response , Against , Merging , Sublineages ,